Skip to main content

Table 3 Patients characteristics

From: Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway

Characteristics

N

%

Patient age, median (range)

51 (12–71)

 

Patient gender

 Male

14

51.85

 Female

13

48.15

Relapse

10

37.04

Refractory

17

62.96

Diagnosis (WHO)

 M1

0

0

 M2

4

14.81

 M4

8

29.63

 M5

12

44.44

 M6

2

7.41

 unavailable

1

3.71

Hb, ×g/L median (range)

96 (71–120)

 

WBC, ×109/L median (range)

3.95 (1.40–49.13)

 

Platelets, × 109/L median (range)

101 (16–226)

 

BM blasts median (range)

27.6 (2.50–97.0)

 

karyotype-risk (n=)a

 Favorable-risk

7

25.93

 Intermediate-risk

1

3.70

 Poor-risk

9

33.33

 Unavailable

10

37.04

DNMT3A mutational status

 Wild-type DNMT3A

18

66.67

 DNMT3Amutation

3

11.11

 Missing

6

22.22

TP53 mutational status

 Wild-type TP53

19

70.37

 TP53 mutation

2

7.41

 Missing

6

22.22

FLT3-ITD mutational status

 Wild-type FLT3-ITD

18

66.67

 FLT3-ITD mutation

3

11.11

 Missing

6

22.22

BCOR mutational status

 Wild-type BCOR

20

74.08

 BCOR mutation

1

3.70

 Missing

6

22.22

NRAS mutational status

 Wild-type NRAS

19

70.37

 NRAS mutation

2

7.41

 Missing

6

22.22

STAG2 mutational status

 Wild-type STAG2

20

74.08

 STAG2 mutation

1

3.70

 Missing

6

22.22

  1. Abbreviations: BM bone marrow, WBC white blood count, HB hemoglobin, PLT Platelet
  2. aCytogenetic groups were defined as follows: favourable – t(8;21), inv. (16), irrespective of the presence of other abnormalities; adverse – monosomy5, monosomy 7, del(5q), abnormal 3q, complex (5 or more chromosomal abnormalities); intermediate – all other abnormal karyotypes, normal karyotype
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us